The MarketWatch Information Division was not involved in the creation of this material.
February 05, 2021 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / February 5, 2021 / Jakubowitz Regulation announces that securities fraud course action lawsuits have commenced on behalf of shareholders of the following publicly-traded providers who purchased shares inside the course durations outlined beneath. Shareholders interested in representing the course of wronged shareholders have right until the lead plaintiff deadline to petition the courtroom. Your means to share in any recovery would not demand that you serve as a lead plaintiff. For extra facts and to talk with our firm without the need of price tag or obligation, stick to the one-way links under.
Penumbra, Inc. (NYSE:PEN)
Get in touch with JAKUBOWITZ ABOUT PEN:
Course Time period: August 3, 2020 – December 15, 2020
Lead Plaintiff Deadline: March 16, 2021
The filed grievance alleges that defendants made materially phony and/or misleading statements and/or unsuccessful to disclose that: (1) that the Jet 7 Xtra Flex had regarded style flaws that manufactured it unsafe for its typical use (2) that Penumbra did not sufficiently tackle the possibility of the Jet 7 Xtra Flex creating major damage and fatalities, which experienced in reality previously transpired (3) that the Jet 7 Xtra Flex was likely to be recalled because of to its safety challenges and (4) as a consequence, Penumbra’s public statements as established forth over ended up materially false and deceptive at all related situations.
GoodRx Holdings, Inc (NASDAQ:GDRX)
Contact JAKUBOWITZ ABOUT GDRX:
Course Interval: September 23, 2020 – November 16, 2020
Guide Plaintiff Deadline: February 16, 2021
The filed complaint alleges that defendants built materially fake and/or misleading statements and/or unsuccessful to disclose that: at the time of the IPO, unbeknownst to traders, Amazon.com, Inc. was acquiring and would before long introduce its individual on the web and cellular prescription treatment ordering and fulfillment provider that would immediately contend with GoodRx. Defendants timed the IPO so that it was priced prior to Amazon introduced its on the web pharmaceutical small business to facilitate the IPO and develop artificial demand from customers for the frequent shares bought therein, as properly to improve the total of cash the Enterprise and the selling stockholders could elevate in the IPO. Provided defendants’ understanding of Amazon’s intention to enter the on the internet pharmaceutical business, and their deceptive statements about GoodRx’s aggressive situation produced contemporaneously with that understanding, defendants’ materially untrue and/or misleading statements alleged herein ended up manufactured willfully and prompted GoodRx popular stock to trade at artificially inflated costs in the course of the Class Period.
QuantumScape Company f/k/a Kensington Money Acquisition Corp. (NYSE:QS)
Contact JAKUBOWITZ ABOUT QS:
Class Time period: November 27, 2020 – December 31, 2020
Guide Plaintiff Deadline: March 8, 2021
The filed complaint alleges that defendants designed materially bogus and/or misleading statements and/or unsuccessful to disclose that: (1) that the Firm’s purported accomplishment related to its stable-state battery power, battery everyday living, and power density were drastically overstated (2) that the Business is unlikely to be able to scale its technology to the multi-layer mobile essential to power electrical automobiles and (3) that, as a consequence of the foregoing, Defendants’ beneficial statements about the Firm’s small business, operations, and potential clients had been materially deceptive and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the target of securities fraud. Attorney advertising and marketing. Prior results do not warranty equivalent outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
Supply: Jakubowitz Legislation
View resource model on accesswire.com:
Copyright 2021 ACCESSWIRE
The MarketWatch News Section was not concerned in the generation of this content.